Retraction: Lysyl Oxidase Polymorphisms and Susceptibility to Osteosarcoma (PLoS ONE (2022) 7:7 (e41610) DOI: 10.1371/journal.pone.0041610);Lysyl oxidase polymorphisms and susceptibility to osteosarcoma

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Liu, Yang ^a   Lv, Bitao ^a   He, Zhimin ^b   Zhou, Yujia ^c   Han, Carrie ^d   Shi, Guodong ^a   Gao, Rui ^a   Wang, Ce ^a   Yang, Lili ^a   Song, Haihan ^e   Yuan, Wen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Branch Hospital in Fengxian of Shanghai No 6 People's Hospital   (China)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYTOSINE; GUANINE; PROTEIN LYSINE 6 OXIDASE;

ADOLESCENT; ADULT; AGED; ALLELE; ALTERNATIVE RNA SPLICING; ARTICLE; CARCINOGENESIS; CHILD; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE FUNCTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; HUMAN CELL; INTRON; LOX GENE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PREVALENCE; PROMOTER REGION; SCHOOL CHILD;

EID: 84864263453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0275707     Document Type: Erratum

References (32)

1. Hameed M, Dorfman H, (2011) Primary malignant bone tumors-recent developments. Semin Diagn Pathol 28: 86-101.
2. Subbiah V, Kurzrock R, (2011) Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol 23: 352-60.
3. Posthuma DeBoer J, Witlox MA, Kaspers GJ, van Royen BJ, (2011) Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 28: 493-503.
4. Boskey AL, (1996) Matrix protein and mineralization: an overview. Connect Tissue Res 35: 357-363.
5. Fratzl P, Gupta HS, Paschalis EP, Roschger P, (2004) Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem 14: 2115-2123.
6. Kagan H, Trackman P, (1991) Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 5: 206-210.
7. Prockop D, Kivirikko K, (1995) Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 64: 403-434.
8. Yamauchi M, (1996) Collagen: the major matrix molecule in mineralized tissues. In: Anderson JJB, Garner S (eds) Calcium and phosphorus in health and disease. CRC Press, New York, 127-141.
9. Knott L, Bailey A, (1998) Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 22: 181-187.
10. Knott L, Whitehead C, Fleming R, Bailey A, (1995) Biochemical changes in the collagenous matrix of osteoporotic avian bone. J Biochem 310: 1045-1051.
11. Eyre DR, Dickson IR, Van Ness K, (1988) Collagen crosslinking in human bone and articular cartilage: age-related changes in the content of mature hydroxypyridinium residues. J Biochem 252: 495-500.
12. Geiger BJ, Steenbock H, Parsons HT, (1933) Lathyrism in the rat. J Nutr 6: 427-442.
13. Shim H, Harris ZL, (2003) Genetic defects in copper metabolism. J Nutr 133: 1527S-1531S.
14. Contente S, Kenyon K, Rimoldi D, Friedman RM, (1990) Expression of gene rrg is associated with reversion of NIH3T3 transformed by LTR-c-H-ras. Science 249: 796-798.
15. Palamakumbura AH, Jeay S, Guo Y, Pischon N, Sommer P, et al. (2004) The propeptide domain of lysyl oxidase induces phenotypic reversion of rastransformed Cells. J Biol Chem 279: 40593-40600.
16. Kuivaniemi H, Korhonen RM, Vaheri A, Kivirikko KI, (1986) Deficient production of lysyl oxidase in cultures of malignantlytransformed human cells. FEBS Lett 195: 261-264.
17. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC, (1998) Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 58: 1285-1290.
18. Krzyzosiak WJ, Shindo-Okada N, Teshima H, Nakajima K, Nishimura S, (1992) Isolation of genes specifically expressed in flat revertant cells derived from activated ras-transformed NIH 3T3 cells by treatment with azatyrosine. Proc Natl Acad Sci USA 89: 4879-4883.
19. Hamalainen ER, Kemppainen R, Kuivaniemi H, Tromp G, Vaheri A, et al. (1995) Quantitative polymerase chain reaction of lysyl oxidase mRNA in malignantly transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene. J Biol Chem 270: 21590-21593.
20. Hajnal A, Klemenz R, Schafer R, (1993) Up-regulation of lysyl oxidase in spontaneous revertants of H-ras-transformed rat fibroblasts. Cancer Res 53: 4670-4675.
21. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS, (1996) Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science 271: 360-362.
22. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, et al. (2003) R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A 100: 8401-8406.
23. Song B, Liu Y, Liu J, Song X, Wang Z, et al. (2011) CTLA-4+49A>G polymorphism is associated with advanced non-small cell lung cancer prognosis. Respiration 82: 439-944.
24. Wang W, Song H, Liu J, Song B, Cao X, (2011) CD86+1057G/A polymorphism and susceptibility to osteosarcoma. DNA Cell Biol 30: 925-929.
25. Ma L, Song H, Zhang M, Zhang D, (2011) Lysyl Oxidase G473A polymorphism is associated with increased risk of coronary artery diseases. DNA Cell Biol 30: 1033-7.
26. Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, et al. (2009) A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res 69: 6685-6693.
27. Corden J, Wasylyk B, Buchwalder A, Sassone-Corsi P, Kedinger C, et al. (1980) Promotor sequences of eukaryotic protein-coding genes. Science 209: 1406-1414.
28. Smale ST, Kadonaga JT, (2003) The RNA polyermase II core promoter. Annu Rev Biochem 72: 449-479.
29. Gao S, Zhao Y, Kong L, Toselli P, Chou IN, et al. (2007) Cloning and characterization of the rat lysyl oxidase gene promoter: identification of core promoter elements and functional nuclear factor I-binding sites. J Biol Chem 282: 25322-37.
30. Pischon N, Mäki JM, Weisshaupt P, Heng N, Palamakumbura AH, et al. (2009) Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype. Calcif Tissue Int 85: 119-126.
31. Siddikuzzaman, Grace VM, Guruvayoorappan C, (2011) Lysyl oxidase: a potential target for cancer therapy. Inflammopharmacology 19: 117-129.
32. Buchinger B, Spitzer S, Karlic H, Klaushofer K, Varga F, (2008) Lysyl oxidase (LOX) mRNA expression and genes of the differentiated osteoblastic phenotype are upregulated in human osteosarcoma cells by suramin. Cancer Lett 265: 45-54.